News, features, and commentary about cancer-related issues ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Read more about the under-prescription of first-line treatments for erectile dysfunction in patients with prostate cancer.

The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

Prostate cancer is the most common cancer in American men, with an estimated 333,830 new cases and 36,320 deaths projected for 2026 for the disease, according to the American Cancer ...

Bayer sued rival Johnson & Johnson for launching a “false advertising campaign” based on flawed data to wrongfully promote ...

The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...

By Puyaan Singh and Sahil Pandey March 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate cancer imaging agent, aimed at improving ...

Bayer has filed a lawsuit against Johnson & Johnson and Janssen Biotech, alleging the companies made false and misleading claims about the efficacy of its prostate cancer drug Nubeqa compared to the ...